Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score
| Autor: | Takehiko Abe, Yuji Kojima, Masayuki Kurosaki, Keiji Tsuji, Haruhiko Kobashi, Takehiro Akahane, Sakura Kirino, Tomomichi Matsushita, Hideo Yoshida, Chitomi Hasebe, Hiroyuki Marusawa, Hiroyuki Kimura, Yasushi Uchida, Atsunori Kusakabe, Masahiko Kondo, Namiki Izumi, Hitoshi Yagisawa, Nobuharu Tamaki, Kouji Joko, Shun Kaneko |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Hepatitis B virus medicine.medical_specialty Carcinoma Hepatocellular Multivariate analysis lcsh:Medicine medicine.disease_cause Gastroenterology Article Hepatitis 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Carcinoma Humans lcsh:Science Proportional Hazards Models Multidisciplinary Framingham Risk Score Hepatology Nucleotides business.industry Proportional hazards model Incidence Incidence (epidemiology) lcsh:R Liver Neoplasms Middle Aged medicine.disease digestive system diseases Risk factors 030220 oncology & carcinogenesis Hepatocellular carcinoma DNA Viral Regression Analysis lcsh:Q Female 030211 gastroenterology & hepatology business Carcinogenesis Liver cancer |
| Zdroj: | Scientific Reports Scientific Reports, Vol 10, Iss 1, Pp 1-9 (2020) |
| ISSN: | 2045-2322 |
| DOI: | 10.1038/s41598-020-69522-w |
| Popis: | Nucleos(t)ide analogs (NA) suppress hepatitis B virus (HBV) replication and reduce the risk of hepatocellular carcinoma (HCC). However, NA cannot suppress carcinogenesis completely in patients with chronic hepatitis B. The aims of this study were to identify risk factors for HCC and develop a refined carcinogenesis prediction model. Patients receiving NA therapy (n = 1,183) were recruited retrospectively from the 16 hospitals. All patients had been receiving NA continuously for more than 1 year until the end of the follow-up. During a median follow-up of 4.9 (1.0–12.9) years, 52 (4.4%) patients developed HCC. A multivariate analysis revealed that male gender, older age, lower platelet counts at the baseline, and detectable HBV DNA during NA therapy were independent predictive factors of HCC development. The PAGE-B score was calculated by using these factors. 240 (20.3%), 661 (55.9%), and 282 (23.8%) patients were classified into low-, intermediate-, and high-risk groups, respectively. In the intermediate- and high-risk group, detectable HBV DNA was significantly associated with a higher risk of HCC development compared with continuously undetectable HBV DNA, respectively (HR 3.338; 95% CI 1.045–10.66/HR 3.191; 95% CI 1.543–6.597). PAGE-B–DNA, which is the combined PAGE-B and HBV DNA status, was valuable for a more refined stratification of PAGE-B. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|